BioPharmSignal logoBioPharmSignal

Biotech News

Exagen to Announce Second Quarter Financial Results on August 4, 2026

Exagen (XGN)ExagenEarnings

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026.

Related news

XGNExagen2026-10-27 13:00 EST

Exagen to Announce Third Quarter Financial Results on November 10, 2026

OSUROraSure Technologies, Inc.2026-10-26 20:05 EST

OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th

IMVTImmunovant2026-10-21 11:00 EST

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

ANABAnaptysBio, Inc.2026-09-21 20:15 EST

Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update

BRLIBio-Reference Laboratories2026-11-04 21:23 EST

OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results

SABSSAB Biotherapeutics2026-10-29 12:30 EST

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

BMYBMYBristol-Myers Squibb Company2026-10-29 10:59 EST

Bristol Myers Squibb Reports Third Quarter Financial Results for 2026

BRLIBio-Reference Laboratories2026-10-28 12:52 EST

OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

BDSXBiodesix2026-10-22 10:00 EST

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

View all latest news

Exagen

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-10-29 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conferences

XGNExagen2026-10-27 13:00 EST

Exagen to Announce Third Quarter Financial Results on November 10, 2026

XGNExagen2026-08-04 12:00 EST

Exagen Inc. Reports Second Quarter 2026 Financial Results

XGNExagen2026-07-28 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conference

XGNExagen2026-07-21 13:00 EST

Exagen to Announce Second Quarter Financial Results on August 4, 2026

Stock data

Close
7.60 USD
Market cap
116.45M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States